文献速递临床试验与 GCP基础与转化研究

经冠状动脉输注间充质干细胞预防急性心肌梗死诱发的心力衰竭:3期随机临床试验(PREVENT-TAHA8)

Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8).
PubMed 文献 · BMJ · 2025-10-29

该3期随机临床试验在伊朗设拉子三家三级医院纳入420例首次ST段抬高型急性心肌梗死且左心室射血分数<40%的患者,按1:2随机接受同种异体沃顿胶来源间充质干细胞经冠状动脉输注加标准治疗或仅标准治疗。最终分析396例,中位随访33.2个月,结果显示干预组心力衰竭发生率、因心力衰竭再入院率及心血管死亡与因心肌梗死或心力衰竭再入院的复合终点均显著降低,6个月左心室射血分数改善显著更优。

要点

  • 经冠状动脉输注间充质干细胞可降低急性心肌梗死后心力衰竭发生率(HR 0.43)。
  • 干预组因心力衰竭再入院风险显著降低(HR 0.22)。
  • 6个月左心室射血分数改善干预组显著优于对照组(β=5.88)。

核心结论

  • 经冠状动脉输注沃顿胶来源间充质干细胞可显著降低急性心肌梗死后心力衰竭发生率、因心力衰竭再入院率及心血管死亡与因心力衰竭或心肌梗死再入院的复合终点,提示该技术可能作为心肌梗死后预防心力衰竭的有价值辅助手段。

研究设计与样本

  • 3期随机临床试验,在伊朗设拉子三家三级医院开展,纳入420例首次ST段抬高型急性心肌梗死且左心室射血分数<40%的患者,按1:2随机分配至干预组或标准治疗组。
  • 最终分析纳入396例(干预组136例,对照组260例),中位随访33.2个月。

主要发现

  • 心力衰竭发生率:干预组2.77/100人年 vs 对照组6.48/100人年(HR 0.43,95%CI 0.21-0.89;P=0.024)。
  • 因心力衰竭再入院:干预组0.92/100人年 vs 对照组4.20/100人年(HR 0.22,95%CI 0.06-0.74;P=0.015)。
  • 心血管死亡与因心肌梗死或心力衰竭再入院的复合终点:干预组2.80/100人年 vs 对照组7.16/100人年(HR 0.39,95%CI 0.19-0.82;P=0.012)。
  • 因心肌梗死再入院:干预组1.23/100人年 vs 对照组3.06/100人年(HR 0.40,95%CI 0.14-1.19;P=0.10),无统计学显著差异。
  • 全因死亡:干预组1.81/100人年 vs 对照组1.66/100人年(HR 1.10,95%CI 0.40-3.02;P=0.86),无统计学显著差异;心血管死亡:干预组0.91/100人年 vs 对照组1.33/100人年(HR 0.68,95%CI 0.18-2.57;P=0.57),无统计学显著差异。

临床怎么用

  • 作者认为,经冠状动脉输注沃顿胶来源间充质干细胞可能作为心肌梗死后预防心力衰竭发生和降低未来不良事件风险的有价值辅助手段。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the effect of intracoronary infusion of mesenchymal stem cells on the development of post-myocardial infarction heart failure. DESIGN: Phase 3 randomised clinical trial. SETTING: Three tertiary hospitals in Shiraz, Iran. PARTICIPANTS: 420 patients with a first ST segment elevation acute myocardial infarction and left ventricular ejection fraction <40% were enrolled and randomised in a 1:2 ratio to receive intervention or standard care. INTERVENTION: Intracoronary infusion of allogenic Wharton's jelly derived mesenchymal stem cells within 3-7 days of acute myocardial infarction in addition to standard care. MAIN OUTCOME MEASURES: The primary endpoint was incidence of heart failure. Secondary endpoints included readmission to hospital for heart failure, all cause mortality, cardiovascular mortality, and readmission to hospital for myocardial infarction. Changes in left ventricular ejection fraction within six months post-myocardial infarction were compared between groups. RESULTS: A total of 396 patients (136 in the intervention group and 260 in the control group) were included in the final analysis, with a median follow-up of 33.2 months. Intracoronary infusion of mesenchymal stem cells had a preventive effect for incidence of heart failure (2.77 v 6.48 per 100 person years; hazard ratio 0.43, 95% confidence interval 0.21 to 0.89; P=0.024), readmission to hospital for heart failure (0.92 v 4.20 per 100 person years; 0.22, 0.06 to 0.74; P=0.015), and a composite endpoint of cardiovascular mortality and readmission for myocardial infarction or heart failure (2.80 v 7.16 per 100 person years; 0.39, 0.19 to 0.82; P=0.012). The intervention did not have a statistically significant effect on readmission to hospital for myocardial infarction (1.23 v 3.06 per 100 person years; hazard ratio 0.40, 0.14 to 1.19; P=0.10), all cause mortality (1.81 v 1.66 per 100 person years; 1.10, 0.40 to 3.02; P=0.86), or cardiovascular mortality (0.91 v 1.33 per 100 person years; 0.68, 0.18 to 2.57; P=0.57). Left ventricular ejection fraction in the intervention group showed a significantly greater improvement from baseline at six months compared with the control group (β=5.88, 95% confidence interval 4.00 to 7.76; P<0.001). CONCLUSIONS: Intracoronary infusion of Wharton's jelly derived mesenchymal stem cells significantly reduced the risk of incidence of heart failure, readmission to hospital for heart failure, and the composite endpoint of cardiovascular mortality and readmission to hospital for heart failure or myocardial infarction in patients after an acute myocardial infarction, suggesting that this technique may serve as a valuable adjunctive procedure after myocardial infarction to prevent the development of heart failure and reduce the risk of future adverse events. TRIAL REGISTRATION: ClinicalTrials.gov NCT05043610.

来源:BMJ,查看原文。版权归原作者所有。

引用

  1. Attar A, Mirhosseini SA, Mathur A, et al. Prevention of acute myocardial infarction induced heart failure by intracoronary infusion of mesenchymal stem cells: phase 3 randomised clinical trial (PREVENT-TAHA8). BMJ. 2025. PMID: 41224473. doi:10.1136/bmj-2024-083382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。